Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
72 participants
INTERVENTIONAL
2019-09-04
2020-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females
NCT04965961
CD71 in Dried Blood Spots in Healthy Males
NCT04073849
Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents
NCT03276910
Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration
NCT00793767
Identification of New Serum Markers for Detection of Abuse With Erythropoietin
NCT01320449
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Saline infusion
Placebo
Subjects receive weekly infusions of saline
EPO
Erythropoetin infusion (9 IU/kg)
Erythropoietin
Subjects receive weekly infusions of EPO
EPO II
Erythropoetin infusion (20 IU/kg)
Erythropoietin
Subjects receive weekly infusions of EPO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythropoietin
Subjects receive weekly infusions of EPO
Placebo
Subjects receive weekly infusions of saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18 and 27
* Resting hematocrit of less than 46%
Exclusion Criteria
* Competitive athlete subject to doping control
* Use of other prescription medicine deemed by the medical doctor to interact with the study drug
* Allergy or otherwise unacceptable side effects toward the study drug
* Smoker
* Pregnancy
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Tasmania
OTHER
Morten Hostrup, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
August Krogh Building
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EPO-EXO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.